rs113298164
Positions:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_000236.3(LIPC):c.1214C>T(p.Thr405Met) variant causes a missense change. The variant allele was found at a frequency of 0.00255 in 1,614,152 control chromosomes in the GnomAD database, including 19 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0028 ( 2 hom., cov: 32)
Exomes 𝑓: 0.0025 ( 17 hom. )
Consequence
LIPC
NM_000236.3 missense
NM_000236.3 missense
Scores
3
7
8
Clinical Significance
Conservation
PhyloP100: 7.18
Genes affected
LIPC (HGNC:6619): (lipase C, hepatic type) Enables phospholipase A1 activity and triglyceride lipase activity. Involved in several processes, including lipid homeostasis; plasma lipoprotein particle remodeling; and triglyceride catabolic process. Located in extracellular space. Implicated in several diseases, including Alzheimer's disease; coronary artery disease; familial combined hyperlipidemia; peripheral vascular disease; and type 2 diabetes mellitus. Biomarker of hyperinsulinism; obesity; and type 1 diabetes mellitus. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.015030295).
BS2
High Homozygotes in GnomAd4 at 2 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LIPC | NM_000236.3 | c.1214C>T | p.Thr405Met | missense_variant | 8/9 | ENST00000299022.10 | NP_000227.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LIPC | ENST00000299022.10 | c.1214C>T | p.Thr405Met | missense_variant | 8/9 | 1 | NM_000236.3 | ENSP00000299022.5 |
Frequencies
GnomAD3 genomes AF: 0.00284 AC: 432AN: 152174Hom.: 2 Cov.: 32
GnomAD3 genomes
AF:
AC:
432
AN:
152174
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00293 AC: 737AN: 251448Hom.: 2 AF XY: 0.00274 AC XY: 372AN XY: 135888
GnomAD3 exomes
AF:
AC:
737
AN:
251448
Hom.:
AF XY:
AC XY:
372
AN XY:
135888
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00252 AC: 3682AN: 1461860Hom.: 17 Cov.: 32 AF XY: 0.00247 AC XY: 1794AN XY: 727228
GnomAD4 exome
AF:
AC:
3682
AN:
1461860
Hom.:
Cov.:
32
AF XY:
AC XY:
1794
AN XY:
727228
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00284 AC: 432AN: 152292Hom.: 2 Cov.: 32 AF XY: 0.00312 AC XY: 232AN XY: 74472
GnomAD4 genome
AF:
AC:
432
AN:
152292
Hom.:
Cov.:
32
AF XY:
AC XY:
232
AN XY:
74472
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
4
ALSPAC
AF:
AC:
6
ESP6500AA
AF:
AC:
2
ESP6500EA
AF:
AC:
16
ExAC
AF:
AC:
335
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:3Uncertain:5Benign:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:2Benign:3
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Nov 09, 2020 | This variant is associated with the following publications: (PMID: 32041611, 31589614, 31980526, 30333156, 28870971, 1671786, 24082139, 24497850, 20981092, 8732782, 1883393, 23685560, 8123642) - |
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 12, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2024 | LIPC: BS1 - |
Hyperlipidemia due to hepatic triglyceride lipase deficiency Pathogenic:2Uncertain:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 2003 | - - |
Likely pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NM_000236.2:c.1214C>T in the LIPC gene has an allele frequency of 0.015 in European(Finnish) subpopulation in the gnomAD database.Functional studies demonstrate that p.Thr405Met has reduced enzymatic activity (PMID: 1883393). It was detected in multiple individuals with autosomal recessive Hepatic lipase deficiency, compound heterozygous with c.1214C>T (p.Thr405Met) (PMID: 1883393).The patient's phenotype is highly specific for LIPC gene (PMID: 1671786). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP criteria applied: PS3; PM3; PP4. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Type 2 diabetes mellitus Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jun 24, 2020 | Variant classified as Uncertain Significance - Favor Pathogenic. The p.Thr405Met variant in LIPC (also reported as p.Thr383Met in the literature) has been identified in the compound heterozygous state in at least 2 individuals with hepatic lipase deficiency and segregated with disease in 5 affected relatives from 2 families (Hegele 1991 PMID: 1883393, Hegele 1991 PMID: 1671786, Ruel 2003 PMID: 12777476 ). This variant has also been identified in the heterozygous state in 3 individuals with biochemical features consistent with hepatic lipase deficiency (Knudsen 1996 PMID: 8732782, Motazacker 2013 PMID: 23685560, Geller 2018 PMID: 30333156). Additionally, this variant has been reported in ClinVar (Variation ID # 14451) and has been identified in 1.5% (388/25112) of Finnish chromosomes, including 3 homozygotes, and 0.3% (460/129166) of European chromosomes, including 2 homozygotes, by gnomAD (http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that this variant impacts protein function (Knudsen 1996 PMID: 8732782, Durstenfeld 1994 PMID: 8123642); however, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain as it is unclear what clinical effect of the biochemical change in lipid levels has on people with hepatic lipase deficiency, particularly on how they affect the risk of atherosclerosis in some individuals and not in others and whether that risk is greater than individuals in the general population (Brunzell 2011 PMID: 21986251, Kobayashi 2015 PMID: 25995285). ACMG/AMP Criteria applied:PP1_Strong, PM3, PS3_Supporting. - |
Type 1 diabetes mellitus 2;C2675071:High density lipoprotein cholesterol level quantitative trait locus 12;C3151466:Hyperlipidemia due to hepatic triglyceride lipase deficiency Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Feb 24, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;.;T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;.;D
MetaRNN
Benign
T;T;T;T
MetaSVM
Uncertain
T
MutationAssessor
Pathogenic
M;.;M;.
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N;N
REVEL
Uncertain
Sift
Benign
D;T;D;T
Sift4G
Benign
T;T;T;T
Polyphen
D;.;D;D
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at